Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Analysis of iodine-125 interstitial therapy in the treatment of localized carcinoma of the prostate

Journal Article · · Journal of Surgical Oncology; (USA)
OSTI ID:5799311
Definitive treatment of localized carcinoma of the prostate has included radical surgery, external beam radiation therapy, and interstitial radiation therapy. The interstitial agent most commonly used is Iodine-125. Forty-eight patients were treated with interstitial radiation therapy using Iodine-125 implants with a median follow-up of 55 months. Forty-three percent of the evaluable patients had progressive disease with approximately 50% progressing at 5 years by Kaplan-Meier analysis. Overall actuarial survival in the group was 80% at 5 years. This and several other studies suggest that control of prostate cancer with Iodine-125 seeds may be suboptimal as compared with other treatment modalities, especially the radical retropubic prostatectomy. Analysis of treatment parameters is presented along with a discussion of the current status and future prospects for treatment of localized carcinoma of the prostate with interstitial radiation therapy.
OSTI ID:
5799311
Journal Information:
Journal of Surgical Oncology; (USA), Journal Name: Journal of Surgical Oncology; (USA) Vol. 46:4; ISSN JSONA; ISSN 0022-4790
Country of Publication:
United States
Language:
English